Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea
· Financial Post
PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s disease (HD) chorea3 and the effect of AUSTEDO® or AUSTEDO XR® on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.1,2 The data were presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, held June 4 – 8, 2026, in Washington, DC. Read More
Visit saltysenoritaaz.org for more information.